{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T22:17:18Z","timestamp":1672006638830},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s12272-001-1257-7","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T06:35:52Z","timestamp":1221114952000},"page":"989-994","source":"Crossref","is-referenced-by-count":3,"title":["5-HT2C receptor agonists with potential anorectic activity"],"prefix":"10.1007","volume":"31","author":[{"given":"Goo","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hoon","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,12]]},"reference":[{"key":"1257_CR1","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1021\/jm058238r","volume":"49","author":"J. Antel","year":"2006","unstructured":"Antel, J., Gregory, P. C., and Nordheim, U., CB1 Cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J. Med. Chem., 49, 4008\u20134016 (2006).","journal-title":"J. Med. Chem."},{"key":"1257_CR2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1039\/B513656C","volume":"8","author":"K. Aplander","year":"2006","unstructured":"Aplander, K., Hidestal, O., Katebzadeh, K., and Lindstrom, U. M., A green and facile route to \u03b3-and \u03b4-lactones via efficient Pinnercyclization of hydroxynitriles in water. Green Chem., 8, 22\u201324 (2006).","journal-title":"Green Chem."},{"key":"1257_CR3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2174\/1568026033452249","volume":"3","author":"M. J. Bickerdike","year":"2003","unstructured":"Bickerdike, M. J., 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr. Top. Med. Chem., 3, 885\u2013897 (2003).","journal-title":"Curr. Top. Med. Chem."},{"key":"1257_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1463-1326.1999.00037.x","volume":"1","author":"M. J. Bickerdike","year":"1999","unstructured":"Bickerdike, M. J., Vickers, S. P., and Dourish, C. T., 5-HT2C receptor modulation and the treatment of obesity. Diabetes Obes. Metab., 1, 207\u201314 (1999).","journal-title":"Diabetes Obes. Metab."},{"key":"1257_CR5","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1021\/jm0680124","volume":"49","author":"G. A. Bray","year":"2006","unstructured":"Bray, G. A., Obesity: The disease. J. Med. Chem., 49, 4001\u20134007 (2006).","journal-title":"J. Med. Chem."},{"key":"1257_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"M. H. Connolly","year":"1997","unstructured":"Connolly, M. H., Crary, J. L., Mcgoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., and Schaff, H. V., Valvular, heart disease associated with fenfluramine-phentermine. New. Enlg. J. Med., 337, 581\u2013588 (1997).","journal-title":"New. Enlg. J. Med."},{"key":"1257_CR7","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1021\/jm058239j","volume":"49","author":"A. L. Handlon","year":"2006","unstructured":"Handlon, A. L. and Zhou, A. H., Melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. J. Med. Chem., 49, 4017\u20134022 (2006).","journal-title":"J. Med. Chem."},{"key":"1257_CR8","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1016\/j.tetlet.2006.05.117","volume":"47","author":"E. A. Krafft","year":"2006","unstructured":"Krafft, E. A., Pinard, E., and Thomas, A. W., An improved synthesis of Lu AA20465. Tet. Lett., 47, 5355\u20135357 (2006).","journal-title":"Tet. Lett."},{"key":"1257_CR9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z. Li","year":"2005","unstructured":"Li, Z., Maglione, M., Tu, W., Mojica, W., Aterburn, D., Shugarman, L., Hilton, L., Suttorp, M., Solomon, V., Shekelee, P. G., and Morton, S. C., Meta-analysis: Pharmacologic treatment of obesity. Ann. Intern. Med., 142, 532\u2013546 (2005).","journal-title":"Ann. Intern. Med."},{"key":"1257_CR10","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1021\/jm058241a","volume":"49","author":"R. P. Nargund","year":"2006","unstructured":"Nargund, R. P., Strack, A. M., and Fong, T. M., Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem., 49, 4035\u20134043 (2006).","journal-title":"J. Med. Chem."},{"key":"1257_CR11","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1021\/jm058240i","volume":"49","author":"B. M. Nilsson","year":"2006","unstructured":"Nilsson, B. M., 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. J. Med. Chem., 49, 4023\u20134034 (2006).","journal-title":"J. Med. Chem."},{"key":"1257_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050407","volume":"133","author":"P. A. Sargent","year":"1997","unstructured":"Sargent, P. A., Sharpley, A. L., Williams, C., Goodall, E. M., and Cowen, P. J., 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (Berlin), 133, 309\u2013312 (1997).","journal-title":"Psychopharmacology (Berlin)"},{"key":"1257_CR13","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0960-894X(00)00400-5","volume":"10","author":"G. S. Welmaker","year":"2000","unstructured":"Welmaker, G. S., Nelson, J. A., Sabalski, J. E., Sabb, A. L., Potoski, J. R., Graziano, D., Kagan, M., Coupet, J., Dunlop, J., Mazandarani, H., Rosenzweig-Lipson, S., Sukoff, S., and Zhang, Y., Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1Hpyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg. & Med. Chem. Lett., 10, 1991\u20131994 (2000).","journal-title":"Bioorg. & Med. Chem. Lett."}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-001-1257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12272-001-1257-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-001-1257-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T12:22:34Z","timestamp":1559564554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12272-001-1257-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s12272-001-1257-7","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}